Presentation is loading. Please wait.

Presentation is loading. Please wait.

Persistent pain management An update

Similar presentations


Presentation on theme: "Persistent pain management An update"— Presentation transcript:

1 Persistent pain management An update
Dr Deepak Ravindran Consultant Pain Medicine, RBH

2 OPIOIDS

3 Aims Opiate update Newer opiates tapentadol Opiate conversion ratios
Driving laws and advice from HCPs

4 Opioids update BPS guidance on prescribing opioids oid_main.pdf Opioid induced hyperalgesia Opioid induced hypogonadism No fentanyl for opioid naïve Refer to specialist when needing more than 180mg/Day morphine equivalent

5 Opioid induced hypogonadism
Occurs in both sexes. More than 100mg/day equivalent Features consistent with depressed pituitary function. Low testosterone, low FSH/LH, Low GH and thyroid function Buprenorphine safest due to mixed action. All others can cause problems If suspected, consider opioid switch to Buprenorphine, test for FSH/LH/Testosterone and refer to endocrine for advice and replacement

6 Conversion ratios Please follow BNF
New document from CCG being reviewed Remember Fentanyl 12mcg patch is 45mg Morphine equivalent and 25mcg patch is 90mg morphine Problems with addiction medicine and methadone dosing

7 Driving laws and changes
Guidance for healthcare professionals on drug driving – July 2014 Came into force March 2015 Roadside drug screening devices developed to detect drugs from saliva All benzodiazepines/methadone/morphine and amphetamines Establishes a statutory medical defence Must keep a copy of their prescription in the vehicle, duty to inform DVLA and insurer

8 Driving laws Patient needs to decide what evidence they will share with police Does not prevent being charged if police have evidence of impairment Ulitmately driver responsibility but HCP expected to warn patient Not to drive if experiencing side effects Not to drive when increasing doses If another medicine is being added or an OTC is added which can impair Developing another medical problem Co-existing alcohol use/abuse

9 Tapentadol New analgesic. Similar to tramadol.
Better side effect profile compared to tramadol and most opioids Has some Mu-opioid action but more noradrenergic action Possibly useful as an opioid switch when all other drugs have failed Presently low priority in Berkshire West Possible role in future for patients on high opiates or neuropathics with side effects, no relief or poor QOL

10 ANTINEUROPATHICS

11 Topics Combinations of amitryptiline and tramadol
Gabapentin and Lyrica (pregabalin) Conversion and switch between both BPS guidance on patient information for drugs: Website has leaflets on Gabapentin, Pregabalin, Nortyptiline, Amitriptyline and Duloxetine

12 Antineuropathics Risk of serotonergic syndrome with high doses of amitriptyline and tramadol Low doses are ok and tolerated Maximum high dose of amitryptiline and nortryptiline for chronic pain is 75mg/day Imipramine and desipramine rarely used

13 Gabapentin and Lyrica Pfizer and Lyrica for pain
Patient on 900mg TDS gabapentin. No benefit. You want to switch to Pregabalin. Do you Taper down and then switch Direct switch to high dose Pregabalin start Pregabalin and then taper gabapentin while increasing Pregabalin

14 Gabapentin and Lyrica Gabapentin has non linear pharmacokinetics. Dose increase is gradual and plasma levels are unpredictable. Transfer from stomach is saturated quickly Effects of increasing the dose are a hit and miss in terms of efficacy and blood levels Lyrica is linear pharmacokinetics. Non saturable. Double the dose and double the concentration.

15 Lyrica Roughly 900mg Gabapentin is equal to 100mg Lyrica
No evidence regarding the safest method for switching SO, upto 300mg TDS of Gabapentin, switch to 50mg BD of Lyrica Any higher doses of Gabapentin, taper it first before switching If any concern then taper further and switch to 25mg BD of Lyrica

16 Fibromyalgia More objective and better criteria for diagnosis
Symptom severity scale and Widespread Pain Index No more 18 tender points Evidence of fMRI changes, biochemical changes Central nervous system dysfunction Newer treatments – lignocaine and LDN

17 Fibromyalgia – local developments
GP and Patient information booklets IPASS has dedicated FMS pain management programmes Patient support group active – branches in Wokingham, Thatcham and Reading Mayors charity, House of Commons debate

18 Further resources RBH pain management website for medication information and patient information leaflets IPASS website being developed British Pain Society website Or via CAB advice and guidance

19 Any questions?


Download ppt "Persistent pain management An update"

Similar presentations


Ads by Google